Aldeyra Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Aldeyra Therapeutics, Inc. on January 28, 2016, reporting events occurring on that date. The filing specifically addresses Item 5.02 regarding the award of performance bonuses to executive officers for the twelve-month period ending December 31, 2015.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation bonuses awarded for the 2015 performance period:
- Todd C. Brady, M.D., Ph.D. (President and CEO): $144,000
- Stephen J. Tulipano (CFO): $94,050
- Scott L. Young (COO): $88,200
Material Changes
The filing reports the execution of a compensatory arrangement approved by the Compensation Committee. No material changes to financial performance, operations, or capital structure are disclosed in this report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a disclosure of the bonus awards.
Key Facts for Investor Verification
- Verify the total cash outflow for executive bonuses ($326,250) against the company's cash position in the most recent 10-Q or 10-K.
- Confirm the specific performance metrics used by the Compensation Committee to justify the 2015 bonus awards.
- Review the company's most recent periodic reports for updated financial status, as this 8-K does not contain financial statements.